The Maharashtra Food and Drug Administration (FDA), led by Commissioner Tukaram Mundhe, has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd’s carrying-and-forwarding (C&F) facility at Wadki in Pune, following regulatory irregularities linked to Reactin Plus Tablets. The cancellation took effect on August 27 after inspections identified issues involving the drug’s packaging, recall procedures, storage arrangements, inventory records and handling of expired medicines.
The action followed a June inspection in which FDA officials found that Reactin Plus, a Schedule H prescription medicine, carried the words “Analgesic and Antipyretic” on its packaging without the required authorization, according to the regulator. The FDA classified the product as misbranded, seized stock valued at about ₹11.19 lakh and directed the company to recall the affected batches. Cipla has challenged the order and said the matter is currently sub judice.
Maharashtra FDA Cancels Cipla Pune Licence
The FDA’s action concerns Cipla Pharma & Life Sciences’ C&F warehouse at Wadki in Pune rather than a manufacturing facility. The regulator’s investigation focused on the handling, storage and distribution of medicines at the site, including the company’s response to the Reactin Plus recall.
Following the initial inspection, the FDA issued directions to the company and subsequently conducted a follow-up inspection. According to the regulator, the follow-up identified additional deficiencies in inventory management, storage practices, recall compliance and documentation.
After issuing a show-cause notice and considering Cipla’s explanation, the FDA decided to cancel the drug sale licences with effect from August 27.
Key Details Of The FDA Action
| Particular | Details |
|---|---|
| Company | Cipla Pharma & Life Sciences Ltd |
| Facility | C&F unit, Wadki, Pune |
| Regulator | Maharashtra FDA |
| Commissioner | Tukaram Mundhe |
| Product involved | Reactin Plus Tablets |
| Drug classification | Schedule H prescription medicine |
| Initial inspection | June 2026 |
| Licence cancellation | August 27, 2026 |
| Stock seized | About ₹11.19 lakh |
| Main issues | Packaging, recall, storage, inventory and records |
| Cipla’s position | Order contested; matter sub judice |
The regulator has emphasized that its action concerns compliance with requirements governing the advertising, sale, storage and distribution of prescription medicines.
Reactin Plus Packaging Triggered Initial Action
The initial FDA inspection in June identified the most prominent issue involving Reactin Plus Tablets.
The packaging reportedly described the medicine as an “Analgesic and Antipyretic.” The FDA said this was unauthorized promotional material and was inconsistent with provisions of the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945.
The regulator subsequently seized Reactin Plus stock worth approximately ₹11.19 lakh and directed Cipla to recall the affected product from the market.
Reactin Plus Regulatory Timeline
June 2026
│
├── FDA inspects Cipla's Wadki warehouse
│
├── Unauthorized claim found on Reactin Plus packaging
│
├── Stock worth ~₹11.19 lakh seized
│
└── Recall directions issued
│
▼
Follow-up inspection
│
├── Inventory discrepancies
├── Storage deficiencies
├── Recall-process concerns
└── Record-keeping deficiencies
│
▼
Show-cause notice
│
▼
August 27, 2026
└── Drug sale licences cancelled
The FDA’s subsequent action was therefore not based solely on the packaging issue. The regulator said the follow-up inspection found additional operational and compliance deficiencies at the C&F facility.
FDA Flags Inventory And Storage Lapses
During the follow-up inspection, FDA officials found discrepancies between purchase and sales records, computerized inventory records and physical stock.
Such discrepancies can make it difficult for regulators and companies to establish exactly where medicines are located, which batches have been distributed and whether recalled products have been successfully removed from the supply chain.
The FDA also cited deficiencies in the physical storage of medicines. Reports said some medicines were found stored directly on the floor, while the facility had inadequate pallets and racks for proper storage.
Violations Cited By Maharashtra FDA
| Compliance Area | FDA’s Reported Finding |
|---|---|
| Product packaging | Unauthorized promotional claim |
| Product classification | Reactin Plus treated as misbranded by regulator |
| Recall | Alleged incomplete compliance with recall directions |
| Inventory | Discrepancies between records and physical stock |
| Storage | Medicines found directly on floor |
| Pallets and racks | Inadequate arrangements |
| Expired medicines | Record/procedure deficiencies |
| Documentation | Gaps in required records and procedures |
The combination of product-labeling concerns and warehouse-management deficiencies led the regulator to take action against the facility’s drug sale licences.
Cipla Contests The FDA Order
Cipla has disputed the regulatory action.
In a statement reported by Business Standard, the company said Cipla Pharma & Life Sciences has contested the Pune FDA’s order concerning the C&F warehouse and that the matter is currently sub judice. The company declined to comment further because the issue is under judicial consideration.
Cipla also made an important clarification about the nature of the action.
The company said the order does not allege concerns relating to the safety, quality or efficacy of its products, nor does it involve or indicate a patient-safety issue.
That distinction is important. The FDA’s action concerns alleged regulatory and distribution-compliance failures at the C&F facility, rather than an official finding that Reactin Plus was unsafe or ineffective.
FDA Allegations Vs Cipla’s Position
| Issue | FDA / Regulatory Position | Cipla’s Position |
|---|---|---|
| Packaging | Unauthorized claim alleged | Order contested |
| Recall | Non-compliance alleged | Matter under judicial consideration |
| Storage | Deficiencies cited | Order challenged |
| Inventory records | Discrepancies cited | Matter sub judice |
| Product safety | Regulatory action taken | No safety issue alleged |
| Product efficacy | — | No efficacy concern alleged |
| Legal status | Licence cancelled | Cancellation contested |
The final legal position will depend on the outcome of the proceedings challenging the FDA order.
What Is A C&F Facility?
A carrying-and-forwarding facility plays an important role in the pharmaceutical distribution chain.
Such facilities typically receive products from manufacturers or company warehouses, store them and facilitate onward distribution to distributors, stockists or other authorized channels.
That makes compliance at these facilities important even when they are not manufacturing medicines.
Storage conditions, batch tracking, inventory reconciliation and recall execution are particularly important because regulators need to be able to trace medicines through the supply chain.
Pharmaceutical Distribution Chain
Manufacturer
│
▼
C&F Warehouse
│
├── Storage
├── Inventory tracking
├── Batch records
└── Recall management
│
▼
Distributor / Stockist
│
▼
Pharmacy / Hospital
│
▼
Patient
A weakness at any stage can complicate a product recall or make it more difficult to establish whether affected stock has been removed from circulation.
Why Schedule H Compliance Matters
Reactin Plus was identified by the FDA as a Schedule H prescription medicine.
Schedule H medicines are subject to specific requirements governing their sale and distribution. The FDA has stressed that strict compliance is particularly important for the advertising, sale, storage and distribution of such prescription products.
The packaging issue therefore attracted regulatory attention not simply because of wording on a box, but because the product’s promotional presentation was allegedly inconsistent with the regulatory framework applicable to prescription medicines.
The FDA’s action demonstrates how labeling and distribution compliance can become significant enforcement issues even when the regulator does not allege a product-quality or patient-safety defect.
Tukaram Mundhe Signals Tougher Enforcement
The action comes as Maharashtra FDA Commissioner Tukaram Mundhe has pursued a more aggressive enforcement approach since taking charge of the state’s food and drug safety operations.
Mundhe has attracted national attention for a broader crackdown on food-safety violations across Maharashtra. Reuters reported earlier this week that his teams had conducted more than 3,000 food-safety raids since he took charge in May, including inspections of major restaurant chains and other businesses.
His approach has emphasized strict compliance and visible enforcement.
In the Cipla case, the FDA again stressed that violations involving medicine safety, advertising, storage and distribution would not be treated leniently.
The Action Comes Amid Greater Regulatory Scrutiny
India’s pharmaceutical sector is subject to extensive regulation covering manufacturing, labeling, distribution, storage and sales.
Regulators have increasingly emphasized the importance of supply-chain traceability as pharmaceutical companies manage large volumes of products across multiple warehouses and distribution channels.
For major drug companies, regulatory compliance therefore extends beyond manufacturing plants to warehouses, distributors and other intermediaries.
The Cipla case highlights how a regulator can take action based on a combination of relatively different deficiencies when they collectively indicate weaknesses in a facility’s compliance systems.
Potential Impact On Cipla
The immediate operational impact is focused on the affected Pune C&F facility and its ability to sell or distribute medicines under the cancelled licences.
The broader impact on Cipla will depend on the outcome of its legal challenge and whether distribution can be shifted to alternative facilities.
Because Cipla is a large pharmaceutical company with a wide distribution network, a single C&F facility licence cancellation does not necessarily imply a disruption to the company’s overall product supply.
However, the case could increase compliance scrutiny across the company’s distribution operations and reinforce the need for tighter controls over labeling, inventory reconciliation, storage and recall procedures.
Areas Investors May Watch
- Outcome of Cipla’s challenge to the FDA order
- Status of the Wadki C&F facility
- Any further regulatory action
- Recall completion and inventory reconciliation
- Potential impact on product distribution
- Compliance measures implemented by Cipla
- Broader regulatory scrutiny of pharmaceutical warehouses
The Bigger Picture
The Cipla licence cancellation is significant primarily as a regulatory-compliance case rather than a product-safety recall. Maharashtra FDA says the Wadki C&F facility had multiple deficiencies involving Reactin Plus packaging, recall procedures, inventory records, storage and expired-medicine handling. Cipla, however, has contested the order and explicitly said the action does not allege concerns over the safety, quality or efficacy of its medicines.
The case also illustrates the expanding scope of pharmaceutical regulation. Drug safety is not limited to how medicines are manufactured; accurate labeling, appropriate storage, traceable inventory and effective recall systems are all critical parts of the supply chain. The action by the Maharashtra FDA under Tukaram Mundhe signals that distribution-level compliance is likely to remain under close scrutiny, particularly for prescription medicines subject to stricter regulatory requirements.
Looking Ahead
The immediate focus will be on Cipla’s legal challenge to the FDA’s order and whether the cancellation remains in force while the matter is considered by the courts. The company has maintained that there is no product safety, quality or efficacy concern, while the FDA has defended its action on the basis of alleged regulatory violations at the C&F facility.
For the pharmaceutical industry, the case could serve as a reminder that compliance systems must cover the entire distribution chain. Companies will likely pay particular attention to prescription-drug labeling, warehouse conditions, inventory reconciliation, expired-product procedures and recall documentation. The outcome of Cipla’s challenge will determine the immediate consequences for the company, but the broader message from the Maharashtra FDA is clear: regulatory compliance in drug distribution is being treated as a public-health priority.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
